comparemela.com

Latest Breaking News On - Harrow health stock - Page 1 : comparemela.com

Harrow Health, Inc. (NASDAQ:HROW) CEO Buys $104,310.00 in Stock

Harrow Health, Inc. (NASDAQ:HROW – Get Free Report) CEO Mark L. Baum acquired 9,000 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were bought at an average cost of $11.59 per share, for a total transaction of $104,310.00. Following the completion of the acquisition, the chief executive officer now […]

Markl-baum
Surface-ophthalmics-inc
Rice-hall-james-associates
Harrow-health-company-profile
Jump-financial
Stifel-financial-corp
Harrow-health
Kennedy-capital-management
Pharmaceuticals-inc
Nasdaq
News-ratings-for-harrow-health-daily

Harrow Health, Inc. (NASDAQ:HROW) Expected to Earn Q1 2024 Earnings of ($0.25) Per Share

Harrow Health, Inc. (NASDAQ:HROW – Free Report) – Investment analysts at B. Riley issued their Q1 2024 earnings per share estimates for shares of Harrow Health in a research note issued to investors on Thursday, March 21st. B. Riley analyst M. Mamtani forecasts that the company will post earnings of ($0.25) per share for the […]

Eton-pharmaceuticals-inc
Goldman-sachs-group-inc
Harrow-health
Nasdaq
Nuveen-asset-management
Harrow-health-stock
Barclays-plc
Surface-ophthalmics-inc
Pricet-rowe-associates-inc
News-ratings-for-harrow-health-daily
Vanguard-group-inc

Westside Investment Management Inc. Lowers Stock Position in Harrow Health, Inc. (NASDAQ:HROW)

Westside Investment Management Inc. reduced its stake in Harrow Health, Inc. (NASDAQ:HROW – Free Report) by 11.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 133,744 shares of the company’s stock after selling 16,865 shares during the quarter. Westside Investment […]

Markl-baum
Zurcher-kantonalbank-zurich-cantonalbank
Pharmaceuticals-inc
News-ratings-for-harrow-health-daily
Harrow-health
Quarter-for-harrow-health
Harrow-health-company-profile
Westside-investment-management-inc
Harrow-health-inc
Exchange-commission
Securities-exchange-commission
Nasdaq

Harrow Health (HROW) Scheduled to Post Earnings on Thursday

Harrow Health (NASDAQ:HROW – Get Rating) is scheduled to release its earnings data after the market closes on Thursday, May 11th. Analysts expect Harrow Health to post earnings of ($0.05) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link. Harrow Health Stock Up […]

United-states
America
American
Earnings-history-for-harrow-health
Harrow-health
Surface-ophthalmics-inc
News-ratings-for-harrow-health-daily
Eton-pharmaceuticals-inc
Pharmaceuticals-inc
Cubist-systematic-strategies
American-century-companies-inc

B. Riley Reaffirms "Buy" Rating for Harrow Health (NASDAQ:HROW)

B. Riley reissued their buy rating on shares of Harrow Health (NASDAQ:HROW – Get Rating) in a research note published on Thursday, PriceTargets.com reports. B. Riley also issued estimates for Harrow Health’s FY2026 earnings at $4.27 EPS and FY2027 earnings at $6.22 EPS. A number of other analysts also recently issued reports on the stock. […]

Harrow-health-inc
Harrow-health-stock
Harrow-health-company-profile
Tower-research-capital
Dorsey-wright-associates
Eton-pharmaceuticals-inc
Barclays-plc
Pharmaceuticals-inc
Surface-ophthalmics-inc
Northwestern-mutual-wealth-management-co
Harrow-health

vimarsana © 2020. All Rights Reserved.